A new era in space-based scientific investigation started with the first all-private astronaut mission in April 2022 — a milestone in enabling the commercial potential of R&D in microgravity. An increasing number of companies are pursuing research in orbit with specific drug target identification or biomanufacturing benefits to accelerate product development pipelines back on Earth. Innovative public-private partnerships are growing the capacity, complexity, and availability of orbital R&D opportunities, making it easier than ever for biotechnology companies to participate.
See NASA astronaut Kjell Lindgren, MD, Crew-4 mission commander, explain from the International Space Station why microgravity experiments open new doors for biomedical research. Dr. Lindgren will answer the moderator’s questions live, and panelists from SpaceX, Axiom Space, Merck, and Redwirewill explore practical applications These experts will discuss the connection between the science conducted 250 miles above our heads with the practical steps to improve medicines, other products, and people’s lives at home here on Earth.